HANSA MEDICAL AB ORD news, videos and press releases
For more news please use our advanced search feature.
HANSA MEDICAL AB ORD - More news...
HANSA MEDICAL AB ORD - More news...
- Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
- Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
- Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
- Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
- Hansa Biopharma to Attend Truist Securities BioPharma Symposium
- Hansa Biopharma to Attend Truist Securities BioPharma Symposium
- Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results
- Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results
- Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial
- Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
- Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis
- Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update
- Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update
- Hansa Biopharma to host Q2 2024 interim results conference call
- Hansa Biopharma to host Q2 2024 interim results conference call
- Hansa Biopharma: increase in number of shares and votes
- Hansa Biopharma: increase in number of shares and votes
- Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
- Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting
- Hansa Biopharma: increase in number of shares and votes
- Hansa Biopharma: increase in number of shares and votes
- Hansa Biopharma interim report January-March 2024
- Hansa Biopharma interim report January-March 2024
- Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
- Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
- Hansa Biopharma publishes 2023 Annual and Sustainability Reports
- Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
- Hansa Biopharma Year-end report January-December 2023
- Hansa Biopharma Year-end report January-December 2023
- Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
